A comparison of remote and in-clinic digital cognitive assessments for older adults in primary care settings.

Louisa Thompson, Ph.D.,[1,2] Charles Eaton, M.D., M.S.,[3,7] Sarah Prieto, Ph.D.,[1,2] Molly Lawrence, B.S.,[1] Stephanie Czech, Ph.D.,[3] Jennifer Rosenbaum, M.D.,[3] David Anthony, M.D.,[3] Rabin Chandran, M.D.,[3] Lauren Kelly, P.A.-C.,[3] Ivy Ngo, M.D.,[3] Arnold Goldberg, M.D.,[3] Caitlin Gillooly, M.D.,[3] Nelson Roque, Ph.D.,[4] Hailey Andrews, B.S.,[4] Caroline Richardson, M.D.,[3] A. Rani Elwy, Ph.D.,[2,8] Richard N. Jones, Sc.D.,[1] Dorene M. Rentz, Psy.D.[5,6]

[1]Department of Psychiatry & Human Behavior, Alpert Medical School of Brown University
[2]Memory & Aging Program, Butler Hospital
[3]Department of Family Medicine, Alpert Medical School of Brown University
[4]The Pennsylvania State University, College of Health and Human Development
[5]Department of Neurology, Massachusetts General Hospital, Harvard Medical School
[6]Center for Alzheimer Research & Treatment, Brigham and Women's Hospital, Harvard Medical School
[7]Department of Epidemiology, School of Public Health, Brown University [8]Center for Healthcare Optimization and Implementation Research, VA Bedford Healthcare System

Correspondence concerning this article should be addressed to Louisa Thompson, Department of Psychiatry, Alpert Medical School, Brown University, Providence, RI. Address: 345 Blackstone Blvd., Providence, RI 02906. Phone: 401-455-6402. E-mail: louisa_thompson@brown.edu

Word count: 3,350

Abstract:

BACKGROUND: Timely identification of mild cognitive impairment (MCI) is critical for maximizing early intervention opportunities in older adults at risk for dementia. This study evaluated the feasibility, acceptability, and validity of novel digital cognitive tests in primary care.

METHODS: In a two-phase pilot study across three clinics, 51 older adults completed digital cognitive assessments remotely on personal devices followed by supervised tablet-based cognitive screening in-clinic and the Montreal Cognitive Assessment (MoCA). Surveys and interviews assessed patient and provider acceptability. Digital test completion rates were examined to assess feasibility.

RESULTS: Completion rates ranged from 61.5% - 76% for the at-home assessments and 81.8% for in-clinic testing. Participants generally preferred at-home testing. Providers found in-clinic testing acceptable but identified barriers related to device access and EMR integration. All but one digital test showed moderate correlations with the MoCA.

CONCLUSION: Digital cognitive screening—whether remote or in-clinic—shows promise for primary care implementation.

Background:

The development of new disease-modifying treatments for Alzheimer's disease (AD) and growing evidence in support of early interventions for modifiable dementia risk factors increasingly highlights the importance of identifying older adults at risk for cognitive decline as early as possible.[1,2] Yet, there are substantial discrepancies between the rates of diagnosis and the actual prevalences of mild cognitive impairment (MCI) and AD among older adults seen in primary care and other general medical settings.[3,4] It is estimated that 92% MCI of cases undiagnosed among Medicare beneficiaries, with even higher rates among Black and Hispanic/Latino older adults.[4] Missed and/or delayed diagnoses not only heighten the risk of disease progression but also limit opportunities for patients to adopt beneficial lifestyle changes, access treatment, and participate in care planning.[5,6]

Despite recent advances in commercially-available plasma AD biomarkers, guidelines from the Alzheimer's Association and the Global CEO Initiative state that tests should only be used in the context of cognitive decline.[7,8] Unfortunately, existing cognitive screening tools are insensitive for accurately detecting MCI, particularly in diverse older adults in primary care.[9] With an estimated 88% of U.S. older adults using the internet regularly, now is the time to investigate alternative digital approaches to cognitive screening.[10] Several digital cognitive assessment tools have been shown to be feasible, valid and highly reliable in cognitively healthy older adults, but most of these tools have not been validated for use in primary care.[11,12] Moreover, given time constraints faced by primary care practitioners, there is growing need to determine whether digital assessments could be self-administered remotely (i.e., at home) by older adults to initiate diagnosis or

supplement ongoing cognitive monitoring. Developing new protocols and best practice guidelines for digital cognitive testing in routine preventative care, such as Medicare Annual Wellness Visits (AWV) is a therefore a high priority.

We sought to identify feasible, acceptable, and valid approaches for integrating digital cognitive screening tools in primary care settings. We designed and conducted the present pilot study to compare two approaches: self-administered, digital assessment at home and supervised digital assessment in the clinic. Our objectives were threefold: 1) Determine if remote and in-clinic digital tests show preliminary feasibility determined by test completion rates; 2) Use a mixed methods approach to characterize the acceptability of digital tests among patients and providers, and 3) Conduct a preliminary comparison of remote versus in-clinic digital assessment for identifying cognitive status using the Montreal Cognitive Assessment (MoCA)[13] as a reference standard cognitive test.

Methods:

Study Design and Description of Clinics:

Data were collected during an iterative, context-informed pilot feasibility study with two phases for testing an original and an adjusted protocol (Protocol 1 and Protocol 2; Figure 1). Planned adjustments from Protocol 1 to Protocol 2 included piloting different remote assessments and evaluating feasibility of a clinic-based protocol prior to introducing the additional MAP study visit. Five primary care providers (PCPs) across three clinics aided in Protocol 1 development through focus groups. Four of these providers (80%) continued data collection for the pilot, and four additional providers were recruited over the course of the study. Clinic A was a hospital-affiliated community clinic with an integrated

behavioral health team and two participating PCPs. Clinic B was a Federally Qualified Health Center with three PCPs. Clinic C was a hospital-affiliated family medicine clinic with three PCPs.

Recruitment & Enrollment:

Using electronic medical record (EMR) searches, we identified potential participants (age range of 55-85, no dementia diagnosis) from each participating PCP's panel. We utilized a multipronged approach for recruiting patient participants to maximize insights for future research. Passive methods included mailings, MyChart messages (clinic A and clinic C only), and waiting room flyers. Direct recruitment included phone calls to MyChart users with preferences indicating willingness to be contacted for research, as well as calls to potential participants identified by the PCP.

Screening was conducted over the phone. Eligibility criteria required participants to be fluent in English for Protocol 1, and in either English or Spanish for Protocol 2. Exclusion criteria were existing dementia diagnosis or other neurological disease, a score of <13 on the telephone version of the MoCA[14], current substance use disorder, acute or unstable psychiatric illness, and motor or sensory conditions that would compromise test validity based on self-report during screening. Consent was collected electronically. Compensation included $20 for remote activities and $40 for the study visit in Protocol 2. The project received approval from the Butler Hospital Institutional Review Board, and all participants provided informed consent.

Digital cognitive assessment protocols:

Online assessment with the BOCA (Protocol 1):

Remote assessment was conducted via smartphone, personal computer, or tablet at two timepoints, approximately 1–4 weeks before the participant's AWV or follow-up, and again within one day of the appointment. Participants received a link to complete the Boston Cognitive Assessment (BOCA) via email and a reminder email or call as needed. The BOCA is a 10-minute test of global cognition.[15] Alternate forms are given for repeat assessment. Strong correlations between BOCA and MoCA are found in memory clinic patients and healthy controls.[15,16] BOCA is sensitive to cerebral amyloid status.[17]

Smartphone assessment with CANTAB and M2C2 (Protocol 2):

Participants were emailed links to complete a 10-minute memory test (Paired Associates Learning; PAL) followed by five days of Mobile Monitoring of Cognitive Change (M2C2) assessments. Progress was monitored, with reminders as needed. The PAL test from the Cambridge Neuropsychological Test Automated Battery (CANTAB^R) is a validated visual learning and memory test recently adapted for smartphones.[18,19] Prior studies show PAL is sensitive to AD biomarkers, distinguishes MCI from normal cognition, and predicts disease progression.[20-22] High-frequency assessment (HFA) using the M2C2 platform was delivered via WebView in the Metricwire Catalyst app. Previously validated and described M2C2 tasks included visuospatial working memory, processing speed, and episodic memory.[23,24] Studies show HFA with M2C2 and similar platforms is reliable, distinguishes MCI from normal cognition, and is sensitive to AD biomarkers.[25-27] Participants completed 4-minute sessions (three tasks plus surveys) in the morning and evening, and a 1-minute processing speed task in the afternoon. Push notifications served as reminders.

<u>Assessment in clinic (Protocols 1 and 2)</u>:

Following remote testing, in-clinic testing was completed via tablet during the participant's PCP appointment using the Linus Health Digital Clock and Recall (DCR™), a 3-5-minute assessment designed for in-clinic self-administration supervised by a healthcare professional.[28] All PCPs opted to administer the assessment themselves, versus training support staff to do it. The test includes 3-word learning, stylus-drawn clock, and 3-word recall. A cloud-based scoring algorithm calculates a total (0–5) and sub-scores. Reports are automatically generated with cutoffs (impaired, intermediate, unimpaired) and recommendations.[28-30]

Cognitive health consultation:

Participants also completed a brief cognitive health consultation. In Protocol 1, the study coordinator conducted consultations in-clinic following the PCP appointment. In Protocol 2, consultation visits were scheduled within one month and completed at the MAP. Consultations included administering the Montreal Cognitive Assessment (MoCA) as a reference standard. Results were reviewed with participants, and resources or referrals were provided. In both phases, impaired scores were shared with PCPs and a MAP clinic referral was offered.

Survey & Interview:

Participants provided feedback via a 5–10-minute REDCap survey developed to assess acceptability, including test preference, difficulty, and usability, as well as comfort and stress associated remote versus in-clinic testing. Provider feedback was collected

through 20–30-minute Zoom interviews after at least five DCR administrations and focused on provider experience and protocol improvement (Sup. 1).

Analysis:

Wilcoxon rank-sum and chi-squared tests were used to examined whether there were differences in education, race, or employment status between enrolled participants (n = 51) and those not enrolled (n = 40). We set a benchmark completion rate of 80% to assess the feasibility of the remote and in-clinic digital cognitive assessment protocols. A brief exit survey assessed acceptability among patient participants, while provider feedback was obtained via semi-structured interview. Test-retest reliability was calculated for the BOCA administered across two timepoints (1-4 weeks apart) for Protocol 1. Convergent validity was tested using Pearson's and Spearman's correlations between digital assessments and the MoCA. Area under the curve (AUC) analyses examined BOCA and DCR accuracy for distinguishing cognitive impairment on the MoCA using a cutoff of 26. During Protocol 1, DCR clock drawing performance was used for calculating the clock drawing scores for the MoCA to avoid practice effects.

Results:

Participants:

A total of 91 older adults (Protocol 1 n = 48; Protocol 2 n = 43) were screened for the study. Of these,18 did not meet eligibility criteria. During Protocol 2, seven declined to consent following the screening due to unwillingness to travel for the study visit. Ultimately, 66 participants provided consent; however, 15 (Protocol 1 n = 9; Protocol 2, n = 6) withdrew or were lost to follow-up before completing any study activities. Reasons

(when given) for withdrawal included not having enough time (n = 2) or needing to focus on other high priority health conditions (n = 1). Overall attrition rate was 22% and the final enrolled sample size was N = 51 (Protocol 1 n = 25; Protocol 2 n = 26). Results indicated no significant differences between screened and enrolled participants in terms of education (p = 0.08), or race (p = 0.75). There was a significant difference in employment status (χ^2 = 9.04, p = .01), with unemployed individuals less likely to be enrolled and retired individuals more likely to be enrolled. See Table 1 for sample characteristics.

Feasibility:

Recruitment: Of approximately 80 PCPs contacted via email, we engaged eight volunteers. Patient recruitment was limited to individuals in the care of our participating PCPs. 650 mail invitations were sent to patients, yielding a 2.6% screening rate. 466 messages were sent via MyChart EMR system, yielding a 3.0% screening rate. Direct recruitment methods were more productive, with screening rates of 17.5% from 252 phone calls to MyChart users, and 35.6% from 45 direct PCP referrals. PCP direct referral was particularly useful at clinic B, which did not use MyChart. There were no significant differences in recruitment method by participant demographics.

Digital assessment completion rates: For Protocol 1, completion rate for BOCA administered at time one (T1), 2-4 weeks in advance of the PCP appointment, was 76%. Six participants were non-compliant with T1 BOCA despite follow-up reminders sent via email. The completion rate for BOCA at time two (T2), at home on the day of the participant's PCP appointment, was 64%, with six out of window completions and three non-compliant. In Protocol 2, the completion rates were 61.5% for CANTAB and 75% for

M2C2. Overall, reasons for incompletes included technical difficulties (n = 6), time commitment (n = 6), and non-compliance (n =3). Across both protocols, the completion rate for the PCP-administered DCR at the patient's appointment was 81.8%. Reasons for not completing the DCR included lack of time (n = 4), technical issues (n = 2), and provider forgetting (n = 2). DCR and BOCA T1 completion rates were not significantly different, z = -0.56, p = .57.

Acceptability:

Patient participants: Thirty-six participants completed feedback surveys across Protocols 1 and 2. The majority (54.3%) preferred completing cognitive testing at home, compared to 22.9% who preferred in-clinic testing, and another 22.8% who said they preferred to do both at-home and in-clinic testing. When asked further about their preference, 69.7% reported feeling more comfortable completing cognitive testing at home, whereas 30.3% felt more comfortable in the clinic. In-clinic testing with the DCR was rated as more difficult by 56.3% compared to the at-home testing. Regarding ease of use (rated on a scale from 1 to 5, with 5 indicating greater ease), participants reported a high level of usability (Mean = 4.14, SD = 0.93). Only 6 participants (16.7%) found cognitive testing to be stressful.

PCP participants: At the time of the pilot phase completion, 5 of the 8 PCPs had completed 5 or more DCR administrations and were invited to do the feedback interview. Overall, four out of five providers gave positive feedback on their use of the DCR and endorsed the tablet assessment technology as easy to use (Sup. Table 1). Main advantages of the DCR were described in comments noting that the technology worked well, patients were comfortable completing it, and providers appreciated being able to

work on other tasks during administration. Barriers to use included finding, charging, and logging into the tablet and assessment platform. Three providers also expressed interest in accessing the report on the tablet, a feature available but not introduced during onboarding. Providers were divided on the assessment duration; one noted the required time as a downside, while others said it was quick or convenient. Recruitment logistics at Clinic B were identified as an area for improvement. Research staff relied on the EMR system at Clinics A and C for participant coordination, while Clinic B's was not accessible to the research team.

Validity:

Digital Clock and Recall (DCR): Spanning Protocol 1 and 2, DCR total score was positively and moderately correlated with MoCA ($r = .60$, $p < .001$, $n = 36$), as well as the BOCA remote test in Protocol 1 ($r = .55$, $p < .01$, $n = 25$). Participants were classified into impaired and unimpaired groups based on a MoCA cutoff of <26.[13] Area under the curve (AUC) analysis indicated a DCR total score AUC of .78 for distinguishing MoCA status (Table 2). The MoCA identified eight individuals as impaired, three of whom were classified as unimpaired on the DCR. In contrast, DCR identified two individuals as impaired and six as borderline who were unimpaired on the MoCA.

Boston Cognitive Assessment (BOCA): BOCA test-retest reliability between the T1 and T2 timepoints was good ($r = .81$, $n = 16$, mean time difference =15.5 days, range 4-33 days). Subsequent analyses collapsed across T1 and T2 to examine only the first BOCA instance for each participant ($n = 25$). BOCA total scores were moderately correlated with MoCA ($r = .671$, $n = 25$). Mean BOCA score was 27.2, SD = 3.25, while mean MoCA score

was 26.4, SD =2.65. AUC analysis indicated a BOCA total score AUC of.78 to distinguish cognitive status (Table 2). A cutoff score for identifying impairment has yet to be established for BOCA. As an exploratory analysis of classification agreement, we applied a percentile-based cutoff to BOCA matching the percentile rank for the MoCA cutoff of <26. MoCA identified six individuals as impaired, three of whom were unimpaired on BOCA. BOCA identified six as impaired, three of whom were unimpaired on MoCA.

<u>Preliminary data for CANTAB and M2C2:</u> 13 out of 15 participants who completed PAL and M2C2 also had complete MoCA data. PAL performance (total first attempt memory score) was not associated with the MoCA (r = .53, p =.06) (Table 2). M2C2 Symbol Search performance was associated with MoCA (r = -.58, p < .05), while Grid Memory performance was not (r = -.02, p > .05) (Table 2).

Discussion:

Our results indicate that both remote, at-home online testing and tablet-based, provider-administered in-clinic testing are feasible and acceptable approaches to cognitive screening for older adults in primary care. However, these approaches may require greater support, resources, and training for providers and patients than are currently available in many settings.

Completion rates, an indicator of feasibility, were similar across remote and in-clinic formats. BOCA (remote) and DCR (in-clinic) achieved the highest completion rates (76% and 81.8%, respectively). Though only DCR met our 80% benchmark, the difference was not statistically significant. Within remote testing, M2C2's higher completion rate (75%)

compared to CANTAB (61.5%) suggests that testing in short bursts over several days is well tolerated by older adults, consistent with the broader literature.[24,26] Reminders and flexible scheduling improved participant adherence, highlighting the need for structured implementation support. Future deployment of unsupervised assessments may benefit from a designated coordinator and integration with EMR or AI tools for setup, reminders, and monitoring.

Ease of use and acceptability in the intended context of use are also critical aspects of digital assessment feasibility. We found that while most of the PCPs in our study felt positive about the digital tool itself, technology usability and workflow integration reduced enthusiasm for some (e.g., the need for separate logins, manual EMR data entry). These findings align with recent literature identifying workflow compatibility as an important feature for digital tool selection among providers.[31] While EMR integration is advancing and has the potential to enhance implementation, protocols that do not rely on EMR may be more scalable for many rural or resource-limited settings.[32]

Completing digital cognitive assessments, both at home and in-clinic, was widely viewed as acceptable from the patient's perspective. More technical challenges arose for patients completing smartphone-based testing in Protocol 2 compared to the browser-based, device-agnostic BOCA used in Protocol 1. Specifically, the most common reason for technical difficulties with the CANTAB task involved browser compatibility, while the most common difficulties with M2C2 related to challenges with app setup and login. These findings suggest that web-based assessments with simple URL links may be most

practical for remote use. Provider feedback further supports this approach, especially if results can be automatically integrated into the EMR for clinical review.

All piloted digital assessments demonstrated preliminary validity, showing moderate correlations with the MoCA consistent with the literature.[17,30] BOCA performed comparably to the supervised, in-clinic DCR in detecting mild cognitive impairment, indicating that remote testing prior to an annual appointment could be a good option for first line screening with adequate support and accessibility. This approach could allow primary care providers to identify at-risk individuals prior to annual visits, enabling targeted follow-up while reducing in-clinic testing demands. Scalable, home-based screening could be particularly valuable given time constraints in primary care and the increasing need for early detection as disease-modifying treatments for Alzheimer's disease emerge.

The study also highlights key considerations for designing and conducting primary care-based cognitive screening implementation studies with minimal facilitation. Our iterative, phased protocol development enabled adaptation across clinics with varying workflows and support resources, an essential step for real-world deployment. Interestingly, providers chose to administer the DCR themselves despite the option to delegate to staff, citing high staff burden and turnover. These insights underscore the need to design tools that minimize added workload. Providing participants with their screening results and educational materials to support brain health awareness was a strength of this study which can be extended to larger implementation efforts.

Recruitment posed a major barrier to study startup. Providers who participated were all university-affiliated and experienced in research, raising concerns about generalizability and the potential for lower adoption in less research-engaged settings. Direct referrals from PCPs proved the most effective recruitment method, while passive approaches were unsuccessful. These findings reinforce the importance of leveraging trusted provider-patient relationships to facilitate participation and suggest that cognitive screening will be most successful when provider-initiated.

The small geographically limited sample also constrains generalizability. Participants were more highly educated and less racially diverse than state averages, which may have influenced performance and validity outcomes. While the MoCA cutoff of <26 was appropriate for our sample, alternative cutoffs or reference standards may be necessary for more diverse populations.[33,34] Finally, while the MoCA offers an initial benchmark for converent validity, more in-depth multimodal validation studies comparing novel digital tools with more extensive cognitive testing, disease biomarkers, and functional assessments are needed before widescale clinical implementation.

Although evaluating clinical outcomes was not a focus of this study, the involvement of patients in the study successfully facilitated several referrals for further evaluation to our memory clinic or with a neuropsychologist. Several participants with low or borderline scores were referred for further evaluation, and some were identified as having potentially treatable contributing conditions. These cases highlight the potential clinical value of integrating cognitive screening into routine care. A focus of future research will include assessing whether early detection via these tools improves dementia care outcomes.

In sum, our findings support the feasibility and acceptability of digital cognitive assessments in primary care but highlight the necessity of supportive infrastructure to ensure successful implementation. Browser-based, unsupervised remote assessments show particular promise as scalable tools for early detection. Continued research with larger, more diverse populations and in varied practice settings will be essential to optimize these tools for widespread adoption.

REFERENCES:

1.   Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. *The Lancet*. 2024;404(10452):572-628.

2.   Baker LD, Espeland MA, Whitmer RA, et al. Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial. *JAMA*. 2025;334(8):681-691. doi:10.1001/jama.2025.12923

3.   Liu Y, Jun H, Becker A, Wallick C, Mattke S. Detection Rates of Mild Cognitive Impairment in Primary Care for the United States Medicare Population. *The Journal of Prevention of Alzheimer's Disease*. 2023;doi:10.14283/jpad.2023.131

4.   Mattke S, Jun H, Chen E, Liu Y, Becker A, Wallick C. Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis. *Alzheimer's Research & Therapy*. 2023;15(1)doi:10.1186/s13195-023-01272-z

5.   Ornish D, Madison C, Kivipelto M, et al. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial. *Alzheimers Res Ther*. 2024;16(1):122.

6.   Fowler NR, Partrick KA, Taylor J, et al. Implementing early detection of cognitive impairment in primary care to improve care for older adults. *J Intern Med*. 2025;298(1):31-45. doi:10.1111/joim.20098

7.   Schindler SE, Galasko D, Pereira AC, et al. Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer's Disease. *Nature Reviews Neurology*. 2024/07/01 2024;20(7):426-439. doi:10.1038/s41582-024-00977-5

8.   Jack Jr CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimer's & Dementia*. 2024;20(8):5143-5169.

9.   Spencer R, Wendell C, Giggey P, et al. Psychometric Limitations of the Mini-Mental State Examination Among Nondemented Older Adults: An Evaluation of Neurocognitive and Magnetic Resonance Imaging Correlates. Article. *Exp Aging Res*. 2013;39(4):382-397. doi:10.1080/0361073X.2013.808109

10.   Mobile and Internet Fact Sheets. Pew Research Center. Accessed June 5, 2025. https://www.pewresearch.org/internet/fact-sheet/mobile/

11.   Cubillos C, Rienzo A. Digital Cognitive Assessment Tests for Older Adults: Systematic Literature Review. Review. *JMIR Ment Health*. 2023;10:e47487. doi:10.2196/47487

12.   Polk SE, Öhman F, Hassenstab J, et al. A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer's disease. *npj Digital Medicine*. 2025;8(1):1-14.

13.   Nasreddine ZS, Phillips NA, Bã©Dirian VR, et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. *J Am Geriatr Soc*. 2005;53(4):695-699. doi:10.1111/j.1532-5415.2005.53221.x

14.   Katz MJ, Wang C, Nester CO, et al. T-MoCA: A valid phone screen for cognitive impairment in diverse community samples. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*. 2021;13(1)doi:10.1002/dad2.12144

15. Gold D, Stockwood J, Boulos K, et al. The Boston cognitive assessment: Psychometric foundations of a self-administered measure of global cognition. *The Clinical Neuropsychologist*. 2022;36(8):2313-2330. doi:10.1080/13854046.2021.1933190

16. Vyshedskiy A, Netson R, Fridberg E, et al. Boston cognitive assessment (BOCA) — a comprehensive self-administered smartphone- and computer-based at-home test for longitudinal tracking of cognitive performance. *BMC Neurol*. 2022;22(1)doi:10.1186/s12883-022-02620-6

17. Padovani A, Caratozzolo S, Galli A, et al. Validation and convergent validity of the Boston cognitive assessment (BOCA) in an Italian population: a comparative study with the Montreal cognitive assessment (MoCA) in Alzheimer's disease spectrum. *Neurol Sci*. 2024:1-8.

18. Barnett JH, Blackwell AD, Sahakian BJ, Robbins TW. The paired associates learning (PAL) test: 30 years of CANTAB translational neuroscience from laboratory to bedside in dementia research. *Translational neuropsychopharmacology*. 2016:449-474.

19. Ashford MT, Aaronson A, Kwang W, et al. Unsupervised Online Paired Associates Learning Task from the Cambridge Neuropsychological Test Automated Battery (CANTAB®) in the Brain Health Registry. *The Journal of Prevention of Alzheimer's Disease*. 2024/03/01 2024;11(2):514-524. doi:10.14283/jpad.2023.117

20. Reijs BLR, Ramakers I, Köhler S, et al. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. *J Alzheimers Dis*. 2017;60(3):1119-1128. doi:10.3233/jad-160766

21. Soldan A, Pettigrew C, Moghekar A, Albert M. Computerized Cognitive Tests Are Associated with Biomarkers of Alzheimer's Disease in Cognitively Normal Individuals 10 Years Prior. *J Int Neuropsychol Soc*. Nov 2016;22(10):968-977. doi:10.1017/s1355617716000722

22. Pettigrew C, Soldan A, Brichko R, et al. Computerized paired associate learning performance and imaging biomarkers in older adults without dementia. *Brain Imaging Behav*. Apr 2022;16(2):921-929. doi:10.1007/s11682-021-00583-9

23. Oravecz Z, Harrington KD, Hakun JG, et al. Accounting for retest effects in cognitive testing with the Bayesian double exponential model via intensive measurement burst designs. Original Research. *Front Aging Neurosci*. 2022-September-26 2022;14doi:10.3389/fnagi.2022.897343

24. Thompson LI, De Vito AN, Kunicki ZJ, et al. Psychometric and adherence considerations for high-frequency, smartphone-based cognitive screening protocols in older adults. *J Int Neuropsychol Soc*. 2024;30(8):785-793. doi:10.1017/S1355617724000328

25. Thompson LI, Kunicki ZJ, Emrani S, et al. Remote and in-clinic digital cognitive screening tools outperform the MoCA to distinguish cerebral amyloid status among cognitively healthy older adults. *Alzheimers Dement (Amst)*. 2023;15(4):e12500-e12500. doi:10.1002/dad2.12500

26. Nicosia J, Aschenbrenner AJ, Balota DA, et al. Unsupervised high-frequency smartphone-based cognitive assessments are reliable, valid, and feasible in older adults at risk for Alzheimer's disease. *Journal of the International Neuropsychological Society : JINS*. 2023;29(5):459-471. doi:10.1017/S135561772200042X

27.   Cerino ES, Katz MJ, Wang C, et al. Variability in cognitive performance on mobile devices is sensitive to mild cognitive impairment: Results from the Einstein Aging Study. *Frontiers in Digital Health*. 2021;3:758031.

28.   Jannati A, Toro-Serey C, Gomes-Osman J, et al. Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia. *Alzheimer's Research & Therapy*. 2024;16(1)doi:10.1186/s13195-023-01367-7

29.   Hammers DB, Fowler NR, Brosch JR, et al. Comparative Performance of the Digital Clock and Recall™ Test, Montreal Cognitive Assessment, and Saint Louis University Mental Status Among Patients in Primary Care. *Alzheimer's & Dementia*. 2023;19:e079034.

30.   Hammers DB, Schulman D, Fowler NR, et al. Performance of Older Adults on the Digital Clock and Recall Test Compared to the Montreal Cognitive Assessment in Primary Care Settings: Hammers et al. *J Gen Intern Med*. 2025:1-9.

31.   Summanwar D, Fowler NR, Hammers DB, Perkins AJ, Brosch JR, Willis DR. Agile Implementation of a Digital Cognitive Assessment for Dementia in Primary Care. *The Annals of Family Medicine*. 2025;23(3):199-206. doi:10.1370/afm.240294

32.   Anzalone AJ, Geary CR, Dai R, Watanabe-Galloway S, McClay JC, Campbell JR. Lower electronic health record adoption and interoperability in rural versus urban physician participants: a cross-sectional analysis from the CMS quality payment program. *BMC Health Serv Res*. 2025/01/23 2025;25(1):128. doi:10.1186/s12913-024-12168-5

33.   Ratcliffe LN, Taylor M, Brittany R, R. SJ, W. LD, and Hewitt KC. Classification statistics of the Montreal Cognitive Assessment (MoCA): Are we interpreting the MoCA correctly? *The Clinical Neuropsychologist*. 2023/04/03 2023;37(3):562-576. doi:10.1080/13854046.2022.2086487

34.   Stimmel MB, Orkaby AR, Ayers E, Verghese J, Nsubayi CK, Weiss EF. Is the Montreal cognitive assessment culturally valid in a diverse geriatric primary care setting? Lessons from the Bronx. *J Am Geriatr Soc*. 2024;72(3):850-857. doi:https://doi.org/10.1111/jgs.18705

ACKNOWLEDGEMENTS:
The research team would like to thank our digital assessment partners, including Dr. Andrey Vyshedskiy (Boston Cognitive Assessment), Dr. Alvaro Pascual-Leone (Linus Health), Martina De Lillo (Cambridge Cognition), Dr. Martin J Sliwinski (M2C2). The Montreal Cognitive Assessment was used with permission.

CONSENT STATEMENT:
The study protocol was approved by the Butler Hospital IRB. All participants provided consent.

CONFLICTS:
All authors have nothing to disclose.

FUNDING:
This work is supported by grants from the NIA (K23AG080159, PI: Thompson) and Rhode Island Advance-CTR (IDeA-CTR, NIGMS U54GM115677).

Keywords: Primary Care, Cognitive Screening, Alzheimer's disease, Mild Cognitive Impairment, Digital Assessment, Early Detection.

Figure 1. Protocol schedules for each phase of piloting.

Note. PCP = Primary Care Provider, t-MoCA and MoCA = Telephone version and standard version, respectively, of the Montreal Cognitive Screening Assessment, BOCA = Boston Cognitive Assessment, DCR = Digital Clock and Recall test, CANTAB PAL = Cambridge Neuropsychological Test Automated Battery Paired Associates Learning test, M2C2 = Mobile Monitoring of Cognitive Change.

Table 1. Demographics

Sample Characteristics (N = 51)	Mean (SD) or N (%)
Age	66.5 (6.3)
Education	15.0 (2.4)
Gender	
female	28 (55%)
male	23 (45%)
Race	
Black or African American	7 (13.7%)
White	44 (86.3%)
Ethnicity	
Hispanic or Latino	1 (2%)
(non-Hispanic or Latino)	50 (98%)
MoCA Total Score	26.7 (2.3)

Table 2. Summary of results of remote online, smartphone, and in-clinic assessments.

	Protocol	Assessment mode	Completions (n/N)	Completion rate (%)	Correlation with MoCA	AUROC MoCA < 26
Boston Cognitive Assessment (BOCA), test #1	1	web link	19/25	76.0	--	--
BOCA test #2 (Day of clinic visit)	1	web link	16/25	64	--	--
BOCA Score (first observed)	1	web link	25/25	--	.671	.776
Paired Associated Learning (PAL) test, CANTAB (total first attempt memory score)	2	Smartphone Online link	16/26	61.5	.53 ^{ns}	.364
Mobile Monitoring of Cognitive Change (M2C2) App 3x daily	2	Smartphone app	15/20	75.0	--	--
M2C2 Symbol Search	--	--	--	--	-.58	.727
M2C2 Grid Memory	--	--	--	--	-.02 ^{ns}	.50
Digital Clock and Recall (DCR)	1 & 2	Tablet	36/44	81.8	.60	.781
MoCA	1 & 2	Paper	36	--	NA	NA

Notes: AUROC, Area under the receiver operating characteristic curve; CANTAB, Cambridge Neuropsychological Test Automated Battery; NA, not applicable, the cognitive health consult MoCA was used as the criterion; ns, P > 05. BOCA "first observed" = the first instance of test completion collapsing across administration time points.